A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of ...

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...

Pharma giant MSD is also developing a SC formulation of its blockbuster checkpoint inhibitor Keytruda (pembrolizumab). In addition to benefiting patients, an SC version could give MSD leverage to ...

Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, ...

COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, ...

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) has shown clinically meaningful responses in pretreated patients ...